Cisplatinum ototoxicity in children, long-term follow up.
OBJECTIVE
To assess the long-term ototoxicity effect of platinum chemotherapy in a series of pediatric patients.


METHODS
A prospective cohort study.


METHODS
Patients who received platinum chemotherapy were identified through review of the pharmacy records from 2000 to 2005. Audiograms pre- and post-treatment with cisplatin were noted. The patients were brought back long after treatment for a repeat audiogram and a questionnaire to assess the impact of ototoxicity on their quality of life.


RESULTS
Forty-nine patients received platinum chemotherapy. Patients' exclusion: two had no pre-chemo audiograms, one had retinoblastoma with congenital hearing loss, three were lost to follow up, five deceased, and seven refused participation. The total number of patients included was 31 with long-term follow up total of 21 patients. The follow up period ranged from 1.5 to 6.6 years (median of 3.4 years). Fourty-two percent (13/31) of the patients suffered from otoxicity (3 mild, 3 moderate, 7 severe-profound). Thirty-three (7/21) of audiograms worsened on long-term follow up. Questionnaire revealed 70% subjective hearing loss with 40% requiring hearing aids.


CONCLUSIONS
Ototoxicity after platinum chemotherapy can present or worsen years after completion of therapy. Therefore, we recommend long-term follow up.
Al-Khatib
Talal
T
Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Canada. talal.al-khatib@mail.mcgill.ca
Cohen
Natasha
N
Carret
Anne-Sophie
AS
Daniel
Sam
S
D000293:Adolescent; D017677:Age Distribution; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001299:Audiometry; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced* / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D009369:Neoplasms / Q000188:drug therapy; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D013997:Time Factors
D000970:Antineoplastic Agents; D002945:Cisplatin